Britain and America have established a landmark trade agreement that will keep zero tariffs on British medicine products being sold in the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to boost funding on pharmaceuticals through the NHS. This pledge ensures that tariffs on these crucial goods will stay at zero for a duration of 36 months.
This agreement follows previous threats to significantly raise import taxes on patented drug imports, with increases floated as high as one hundred percent.
"This arrangement with the Britain bolsters the international landscape for innovative medicines and establishes much-needed fairness to transatlantic drug exports," a statement noted.
Economic Significance
Medicines represent one of the the United Kingdom's largest goods shipped to the United States, which is by far the primary destination for large British pharmaceutical firms.
Statistics indicate that in the one-year period to the end of last September, the UK exported medicines totaling billions to the US. This figure accounted for a significant portion of all goods exports in that span.
"This agreement secures employment, increases capital expenditure and facilitates the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The agreement includes several notable changes from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to increase overall health service expenditure on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage drug companies must refund to the NHS to prevent overspending will be capped at 15%. Last year, repayments were more than 20%.
Recent Tensions
The pact comes amid a ongoing row between the sector and the British authorities over drug pricing and NHS adoption.
The disagreement were intensified by claims that US patients were charged a premium for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been paused or cancelled, while multi-billion-dollar investments have been pledged toward American operations.
One official acknowledged that the NHS needed to spend more on medicines, noting that its expenditure on drugs had decreased as a share of its resources over the last ten years.
